The development of novel bioresorbable vascular scaffolds market that aid patients with cardiovascular diseases is another factor driving the market for these scaffolds over the upcoming years. As an illustration, the US Food and Drug Administration approved Abbott's Absorb GT1 bioresorbable vascular scaffold in July 2016. (BVS). In patients with ischemic heart disease caused by de novo native coronary artery lesions, the product improves coronary luminal diameter over time and fully resorbs.
Read More:
https://knackersblogger.blogspot.com/2022/11/cardiovascular-diseases-is-expected-to.html
Sign in to leave a comment.